AKT2 mutation coexisted with EGFR and PIK3CA mutations was associated with lung cancer.

The positive expression of p-AKT2 in lung adenocarcinoma was higher than that in lung squamous carcinomas.

Data suggest that Akt2/B23 functions as an oncogenic unit to drive tumorigenesis of A549 lung cancer cells.

Angiopoietin-2, an angiogenic regulator, promotes initial growth and survival of breast cancer metastases to the lung through the integrin-linked kinase (ILK)-AKT1,2-B cell lymphoma 2 (Bcl-2) pathway.

amplification of AKT1 and/or AKT2 and high-level polysomy were found in 16% of total lung carcinoma cases, and this defined subset was characterized by the overexpression/activation of Akt, reciprocal to EGFR aberrations.

Findings suggest that adding chloroquine to EGF receptor (EGFR) and AKT2 inhibition has the potential to improve tumor responses in EGFR M+ non-small cell lung cancer (NSCLC).

Akt2 role in the human lung cancer cell proliferation, growth, motility, invasion and endothelial cell tube formation

Data show while overexpression of AKT serine/threonine kinase 1 (AKT1) promoted local tumor growth, downregulation of AKT1 or overexpression of AKT serine/threonine kinase 2 (AKT2) promoted peritumoral invasion and lung metastasis.

AKT2 increases the migration and invasion of ovarian cancer cells in vitro and promotes lung metastasis in nude mice in vivo through PKM2-mediated elevation of STAT3 expression and NF-kappaB activation.

Knockdown of HSDL2 inhibits lung adenocarcinoma progression via down-regulating AKT2 expression.

Akt2 coexpresssion markedly increased the incidence of pulmonary metastases in both tumor models, demonstrating a unique role in tumor progression

Loss of Akt2 enhanced lung tumor development.

Akt2(-/-) mice survive hepatic Akt1 deletion but all develop spontaneous hepatocellular carcinoma. They are insulin resistant. Akt2(-/-) mice are not resistant to diethylnitrosamine hepatocarcinogenesis. They have a high incidence of lung metastasis.